New investigations on retatrutides, a dual stimulant for GLP-1 and gastric inhibitory polypeptide, suggest encouraging results in managing excess body fat and type 2 diabetes. Preliminary evidence from clinical experiments reveal considerable diminutions in body bulk and bettered glucose regulation. Further examination is focused on long-term sa… Read More